Drug profile · INN
trovafloxacin mesylate
TROVAN
trovafloxacin mesylate (TROVAN) is a bacterial dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — trovafloxacin mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
trovafloxacin mesylate (TROVAN) is a bacterial dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial DNA gyrase inhibitor
Primary target: Bacterial DNA gyrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is trovafloxacin mesylate?
trovafloxacin mesylate (TROVAN) is a bacterial dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for trovafloxacin mesylate?
TROVAN is a marketed brand name for trovafloxacin mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trovafloxacin mesylate?
trovafloxacin mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.